Women’s health company Evvy raised $40 million in a Series B round led by Catalio Capital Management, supporting its expansion from vaginal microbiome analysis into fertility research and other areas related to women’s health.
The company was founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro. It became known for offering what it describes as the only at-home test of its kind for analyzing vaginal microbes using metagenomic next-generation sequencing (mNGS), with the test holding CLIA and CLEP certifications, according to the company.
How does the platform work?
Evvy receives the swab sample collected by the user at home and sent to the company’s laboratory. After analyzing it using its proprietary mNGS technology, the results are referred to physicians registered on the platform for review and are then published in the patient’s health portal.
The result is not limited to displaying laboratory data; the company says users receive a diagnosis, clinical interpretation, and next steps, including a personalized treatment prescription when appropriate. According to Evvy, the platform currently serves more than 100,000 patients in the United States and collaborates with 3,000 healthcare practitioners.
The company says it has produced 15 papers or published abstracts in peer-reviewed journals, identified new subtypes of bacterial vaginosis, and discovered hundreds of previously unindexed genomes of vaginal microbes.
From testing to a research database
Evvy believes the platform’s value lies not only in treating current conditions but also in building a database linking microbiome biology with symptoms, interventions, and health outcomes. According to Priyanka Jain, this data can help physicians provide more personalized treatments and enable the discovery of new biomarkers through a continuous cycle of data collection and improved care.
In May, the company launched an artificial intelligence assistant called EvvyAI. It says the assistant converts the data collected by the company into immediate guidance for users, while directing questions requiring specialist input to physicians.
Expanding into fertility
Evvy is now entering the fertility field, its first major expansion beyond vaginal health. The company is collecting data to study potential links between the vaginal microbiome and infertility, reproductive-system cancer, preterm birth, in vitro fertilization success rates, and recurrent pregnancy loss. Last year, it also launched a prospective study using microbiome tests inside in vitro fertilization clinics.
Why does this news matter?
The real development lies in Evvy’s transition from an at-home test and clinical analysis to an attempt to build a broad data layer on women’s health that can be used in research and treatment personalization. This matters to the medical technology sector because the company connects molecular data with clinical data and treatment outcomes—links it says traditional medicine has not studied sufficiently.
However, the source does not yet establish that this data improves fertility outcomes or predicts cancer or preterm birth. These applications remain in the data-collection and research stage, and EvvyAI’s stated role is to provide guidance and refer users to physicians when necessary, not to replace medical evaluation. Therefore, the generalizability of the findings, data quality, and proof of actual clinical benefit will remain among the key open questions.